Funding

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)

Published: 15 January 2025
Categories: National Institute of Health-Grants

RSS feed source: National Institute of Health

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Mental Health (NIMH)

Funding Opportunity Title

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)

Activity Code

U19 Research Program – Cooperative Agreements

Announcement Type

Related Notices

April 4, 2024 – Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084.August 31, 2022– Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.August 5, 2022– Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.

Funding Opportunity Number (FON)

Click this link to continue reading the article on the source website.

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)

Published: 15 January 2025
Categories: National Institute of Health-Grants

RSS feed source: National Institute of Health

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Mental Health (NIMH)

Funding Opportunity Title

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)

Activity Code

U01 Research Project – Cooperative Agreements

Announcement Type

Related Notices

April 4, 2024 – Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice NOT-OD-24-084.August 31, 2022– Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.August 5, 2022– Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.

Funding Opportunity Number (FON)

Click this link to continue reading the article on the source website.

Notice of Change to Receipt Date and the Expiration Date for RFA-RM-24-010

Published: 15 January 2025
Categories: National Institute of Health-Grants

RSS feed source: National Institute of Health

Notice of Change to Receipt Date and the Expiration Date for RFA-RM-24-010: Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional)

Notice Number:

NOT-RM-25-001

Release Date:

January 15, 2025

Related Announcements

December 10, 2024 – Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional). See NOFO RFA-RM-24-010.

Issued by

Purpose

The purpose of this notice is to change the new application receipt date and expiration date for Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional) RFA-RM-24-010. The new application receipt date is March 18, 2025. The new expiration date: March 19, 2025. Changes to the Notice of

Click this link to continue reading the article on the source website.

Notice of Special Interest (NOSI): Common Mechanisms and Interactions Among Neurodegenerative Diseases

Published: 15 January 2025
Categories: National Institute of Health-Grants

RSS feed source: National Institute of Health

Notice of Special Interest (NOSI): Common Mechanisms and Interactions Among Neurodegenerative Diseases

Background

Etiologic and therapeutic research on dementia has focused either on individual disease syndromes (e.g., Alzheimer’s disease (AD), Lewy Body Dementia (LBD), Frontotemporal Dementia (FTD), Vascular Contributions to Cognitive Impairment and Dementia (VCID) or distinct neurodegenerative processes (e.g., beta-amyloid, HPF-tau, alpha-synuclein, TDP-43, small vessel changes). Aside from descriptive, postmortem neuropathology, different neurodegenerative diseases have generally been investigated in isolation from one another. There are few models for studying whether and how neurodegenerative disease processes relate to one another.

At autopsy, many patients with dementia, particularly older individuals, exhibit multiple neuropathological changes. In addition to tau tangles and beta-amyloid plaques, vascular changes, Lewy bodies, and TDP-43 inclusions are often present. The likelihood of antemortem dementia increases with co-occurring postmortem neuropathological burden. However, despite considerable evidence of interactions between

Click this link to continue reading the article on the source website.